Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar-Apr;31(2 Suppl 76):166-71.
Epub 2013 Jul 23.

Treatment of early diffuse systemic sclerosis skin disease

Tracy M Frech  1 , Victoria K Shanmugam, Ami A Shah, Shervin Assassi, Jessica K Gordon, Faye N Hant, Monique E Hinchcliff, Virginia Steen, Dinesh Khanna, Cristiane Kayser, Robyn T Domsic
Affiliations
Review

Treatment of early diffuse systemic sclerosis skin disease

Tracy M Frech et al. Clin Exp Rheumatol. 2013 Mar-Apr.

Abstract

Diffuse systemic sclerosis carries a high morbidity and mortality. The Prospective Registry of Early Systemic Sclerosis (PRESS), a multicentre incident cohort study of patients with early diffuse cutaneous systemic sclerosis, has the goal of advancing the understanding of disease pathogenesis and identifying novel biomarkers. In this review, PRESS investigators discuss the evidence pertaining to the more commonly used treatments for early diffuse SSc skin disease including methotrexate, mycophenolate, cyclophosphamide, azathioprine, and intravenous immunoglobulin. This review highlights the unmet need for effective treatment in early diffuse SSc as well as its more rigorous study. Nonetheless, the PRESS investigators aim to decrease intra- and inter-institutional variability in prescribing in order to improve the understanding of the clinical course of early diffuse SSc skin disease.

PubMed Disclaimer

References

    1. LeRoy EC, Medsger TA., Jr Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573–1576. - PubMed
    1. Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15:102–109. - PubMed
    1. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42–53. - PubMed
    1. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am. 2008;34:1–15. v. - PubMed
    1. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6:112–116. - PubMed

Publication types

MeSH terms